Загрузка...
Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
Primary effusion lymphoma (PEL) is caused by Kaposi’s sarcoma-associated herpesvirus (KSHV). PEL has a highly active mTOR pathway, which makes mTOR a potential therapeutic target. MLN0128 is an ATP-competitive inhibitor of mTOR that has entered clinical trials for solid tumors. Our results demonstra...
Сохранить в:
| Опубликовано в: : | mBio |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society for Microbiology
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6381283/ https://ncbi.nlm.nih.gov/pubmed/30782662 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/mBio.02871-18 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|